Sigyn Therapeutics discloses PCT patent filing for chemo delivery enhancement system

Sigyn Therapeutics, Inc.

PCT application entitled 'SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY' submitted.
Technologies ChemoPrep and ChemoPure aim to increase tumor-site drug delivery and reduce off-target toxicity.
PCT allows simultaneous patent protection in over 150 countries; related US provisional previously filed.
Company plans first-in-human studies for Sigyn Therapy; candidate indications include sepsis and pneumonia.
Reduced chemo dosing may alleviate nationwide drug shortages, per the release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.